XIG: CodeSystem/cs-riskfactor-eu-pcsp

FHIR IG Statistics: CodeSystem/cs-riskfactor-eu-pcsp

Package	hl7.eu.fhir.pcsp
Resource Type	CodeSystem
Id	cs-riskfactor-eu-pcsp
FHIR Version	R4
Source	http://hl7.eu/fhir/ig/pcsp/https://build.fhir.org/ig/hl7-eu/pcsp/CodeSystem-cs-riskfactor-eu-pcsp.html
URL	http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp
Version	0.2.0
Status	draft
Date	2025-08-02T17:28:17+00:00
Name	CsRiskFactorPcsp
Title	Risk Factors
Realm	eu
Authority	hl7
Description	Risk Factors used by the PCSP algorithm
Content	complete

Resources that use this resource

ValueSet
vs-riskfactor-eu-pcsp	Risk Factors

Resources that this resource uses

No resources found

Narrative

Note: links and images are rebased to the (stated) source

Generated Narrative: CodeSystem cs-riskfactor-eu-pcsp

This case-sensitive code system http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp defines the following codes:

Code	Display	Definition
1.1	RT to a vol exposing the thyroid gland	RT to a vol exposing the thyroid gland
1.2	TBI	TBI
1.3	MIBG therapy (I-131 MIBG therapy)	MIBG therapy (I-131 MIBG therapy)
2.1	RT >= 10 Gy to a vol exposing the breasts	RT >= 10 Gy to a vol exposing the breasts
2.2	OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age	OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age
3.1	RT >= 35 Gy to a vol exposing the heart	RT >= 35 Gy to a vol exposing the heart
3.2	Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2	Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2
3.3	RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2	RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2
4.1	Alkylating agents	Alkylating agents
4.2	RT to a vol exposing the testes	RT to a vol exposing the testes
4.3	Including TBI	Including TBI
5.1	RT >=12 Gy to a vol exposing the testicles	RT >=12 Gy to a vol exposing the testicles
6.3	Surgery to the spinal cord, sympathetic nerves or pelvis	Surgery to the spinal cord, sympathetic nerves or pelvis
6.4	Hypogonadal	Hypogonadal
7.2	RT to a vol exposing the ovaries	RT to a vol exposing the ovaries
8.1	RT >= 30 Gy to a vol exposing the head or the brain	RT >= 30 Gy to a vol exposing the head or the brain
8.2	Cisplatin (with or without carboplatin > 1500 mg/m2)	Cisplatin (with or without carboplatin > 1500 mg/m2)
9.1	RT to a vol exposing the pancreas	RT to a vol exposing the pancreas
10.2	HSCT	HSCT
11.1	RT to a volume exposing the hypothalamus or pituatary gland	RT to a volume exposing the hypothalamus or pituatary gland
11.3	Hypothalamic or pituitary tumour	Hypothalamic or pituitary tumour
11.4	Neurosurgery of the hypothalamus or pituitary gland	Neurosurgery of the hypothalamus or pituitary gland
12.1	RT to a vol exposing the kidneys, heart and associated large vessels	RT to a vol exposing the kidneys, heart and associated large vessels
12.3	Nephrectomy	Nephrectomy
12.4	Ifosfamide	Ifosfamide
12.5	Platinium based chemotherapy	Platinium based chemotherapy
12.6	Nitrosureas	Nitrosureas
12.7	Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously)	Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously)
13.1	Cranial and/or spinal RT	Cranial and/or spinal RT
13.3	Methotrexate	Methotrexate
13.4	Gonadal failure	Gonadal failure
13.5	Growth hormone deficiency	Growth hormone deficiency
13.6	Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment	Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment
13.7	HSCT, especially with an history of GVHD	HSCT, especially with an history of GVHD
14.3	High dose RT	High dose RT
15.1	Radiotherapy to a vol exposing the HP region >= 30 Gy	Radiotherapy to a vol exposing the HP region >= 30 Gy
15.2	Surgery near or within the HP region	Surgery near or within the HP region
15.3	CNS tumours near or within the HP region	CNS tumours near or within the HP region
16.1	Radiotherapy to a vol exposing the HP region< 30 Gy	Radiotherapy to a vol exposing the HP region< 30 Gy
16.2	Hydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD)	Hydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD)
17.1	Radiotherapy to a vol exposing the HP region	Radiotherapy to a vol exposing the HP region
17.5	hydrocephalus or cerebrospinal fluid shunt	hydrocephalus or cerebrospinal fluid shunt
19.3	Radioiodine therapy (I-131 ablation therapy)	Radioiodine therapy (I-131 ablation therapy)
19.5	Allogenic HSCT	Allogenic HSCT
19.6	Total thyroidectomy	Total thyroidectomy
20.1	RT to a vol exposing the head, brain or neck	RT to a vol exposing the head, brain or neck
21.1	History of a central nervous system tumor	History of a central nervous system tumor
21.2	RT to a vol exposing the brain ANY DOSE	RT to a vol exposing the brain ANY DOSE
21.4	Brain surgery	Brain surgery
21.5	High dose cytarabine IV (intravenous)	High dose cytarabine IV (intravenous)
21.6	High dose MTX IV	High dose MTX IV
21.7	Any Chemotherapy IT (intrathecal)	Any Chemotherapy IT (intrathecal)
22.1	Vinca-Alkaloids	Vinca-Alkaloids
22.2	Cisplatin or carboplatin	Cisplatin or carboplatin
23.1	RT to a vol exposing the lens	RT to a vol exposing the lens
24.1	RT to a vol exposing the eye and orbit	RT to a vol exposing the eye and orbit
25.1	RT to a vol exposing the craniofacial area, especially after high doses and at a young age	RT to a vol exposing the craniofacial area, especially after high doses and at a young age
25.3	Surgery to the face, especially at a young age	Surgery to the face, especially at a young age
26.1	Surgery of the spine	Surgery of the spine
26.2	Surgery of the chest (Does not include CVC pose)	Surgery of the chest (Does not include CVC pose)
26.3	RT to a vol exposing the spine	RT to a vol exposing the spine
26.4	Spinal or paraspinal malignancies	Spinal or paraspinal malignancies
27.1	Cyclophosphamide	Cyclophosphamide
27.3	RT to a vol exposing the bladder	RT to a vol exposing the bladder
27.5	Cystectomy	Cystectomy
27.6	Hysterectomy	Hysterectomy
27.7	Pelvic surgery	Pelvic surgery
27.8	Spinal cord surgery	Spinal cord surgery
28.1	RT to a vol exposing the uterus only female	RT to a vol exposing the uterus only female
29.1	RT to a vol exposing the oral cavity or salivary glands	RT to a vol exposing the oral cavity or salivary glands
29.4	Chemotherapy	Chemotherapy
30.1	RT to a vol exposing the gastro-intestinal tract	RT to a vol exposing the gastro-intestinal tract
30.3	Oesophageal surgery	Oesophageal surgery
30.4	Abdominal surgery	Abdominal surgery
30.5	With a history of chronic GVHD	With a history of chronic GVHD
31.1	Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2	Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2
32.1	RT to a vol exposing the lungs	RT to a vol exposing the lungs
32.3	Bleomycin	Bleomycin
32.4	Busulfan	Busulfan
32.5	BCNU Carmustine	BCNU Carmustine
32.6	CCNU Lomustine	CCNU Lomustine
32.7	Thoracic surgery	Thoracic surgery
33.1	Cisplatin Any dose	Cisplatin Any dose
33.2	Ifosfamide Any dose	Ifosfamide Any dose
33.3	Carboplatin Any dose	Carboplatin Any dose
34.1	RT to a volume exposing the liver	RT to a volume exposing the liver
34.10	Chronic GVHD	Chronic GVHD
34.11	Liver surgery	Liver surgery
34.3	HSCT (irrespective of GVHD)	HSCT (irrespective of GVHD)
34.5	Mercaptopurine Thioguanine	Mercaptopurine Thioguanine
34.6	Dactinomycin	Dactinomycin
34.8	Chronic viral hepatitis	Chronic viral hepatitis
34.9	Sinusoidal obstruction syndrome	Sinusoidal obstruction syndrome
35.1	HSCT (irrespective of GVHD)	HSCT (irrespective of GVHD)
35.2	Multiple red blood cell transfusions	Multiple red blood cell transfusions
36.1	Splenectomy	Splenectomy
36.2	RT >= 10 Gy to a vol exposing the spleen	RT >= 10 Gy to a vol exposing the spleen
36.3	Allogenic HSCT (with or without TBI)	Allogenic HSCT (with or without TBI)
36.4	Autologus HSCT conditioned with TBI	Autologus HSCT conditioned with TBI
37.1	Hereditary cancer sd	Hereditary cancer sd
38.1	Any RT including TBI (predominantly in the RT field)	Any RT including TBI (predominantly in the RT field)
38.2	HSCT Especially with a history of skin GvHD	HSCT Especially with a history of skin GvHD
39.1	RT to a vol exposing the colon and rectum	RT to a vol exposing the colon and rectum
40.1	RT to a vol exposing the oral cavity	RT to a vol exposing the oral cavity
41.2	Anthracyclines and/or Mitoxantrone	Anthracyclines and/or Mitoxantrone
41.3	Epipodophyllotoxins or autologous	Epipodophyllotoxins or autologous
41.4	Autologous haematopoietic stem cell transplant	Autologous haematopoietic stem cell transplant
42.1	Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis)	Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis)
45.1	RT to a vol exposing the head or brain	RT to a vol exposing the head or brain
46.1	RT between 15 and 35 Gy to a vol exposing the heart	RT between 15 and 35 Gy to a vol exposing the heart
46.2	Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2	Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2
47.1	RT to a vol exposing the kidney or urinary tract	RT to a vol exposing the kidney or urinary tract

Source

{
  "resourceType": "CodeSystem",
  "id": "cs-riskfactor-eu-pcsp",
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "url": "http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp",
  "version": "0.2.0",
  "name": "CsRiskFactorPcsp",
  "title": "Risk Factors",
  "status": "draft",
  "experimental": false,
  "date": "2025-08-02T17:28:17+00:00",
  "publisher": "PanCareSurPass Project",
  "contact": [
    {
      "name": "PanCareSurPass Project",
      "telecom": [
        {
          "system": "url",
          "value": "https://www.pancaresurpass.eu/"
        }
      ]
    },
    {
      "name": "PanCareSurPass Project",
      "telecom": [
        {
          "system": "url",
          "value": "https://www.pancaresurpass.eu/"
        }
      ]
    }
  ],
  "description": "Risk Factors used by the PCSP algorithm",
  "jurisdiction": [
    {
      "coding": [
        {
          "system": "http://unstats.un.org/unsd/methods/m49/m49.htm",
          "code": "150",
          "display": "Europe"
        }
      ]
    }
  ],
  "caseSensitive": true,
  "content": "complete",
  "count": 112,
  "concept": [
    {
      "code": "1.1",
      "display": "RT to a vol exposing the thyroid gland",
      "definition": "RT to a vol exposing the thyroid gland"
    },
    {
      "code": "1.2",
      "display": "TBI",
      "definition": "TBI"
    },
    {
      "code": "1.3",
      "display": "MIBG therapy (I-131 MIBG therapy)",
      "definition": "MIBG therapy (I-131 MIBG therapy)"
    },
    {
      "code": "2.1",
      "display": "RT >= 10 Gy to a vol exposing the breasts",
      "definition": "RT >= 10 Gy to a vol exposing the breasts"
    },
    {
      "code": "2.2",
      "display": "OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age",
      "definition": "OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age"
    },
    {
      "code": "3.1",
      "display": "RT >= 35 Gy to a vol exposing the heart",
      "definition": "RT >= 35 Gy to a vol exposing the heart"
    },
    {
      "code": "3.2",
      "display": "Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2",
      "definition": "Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2"
    },
    {
      "code": "3.3",
      "display": "RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2",
      "definition": "RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2"
    },
    {
      "code": "4.1",
      "display": "Alkylating agents",
      "definition": "Alkylating agents"
    },
    {
      "code": "4.2",
      "display": "RT to a vol exposing the testes",
      "definition": "RT to a vol exposing the testes"
    },
    {
      "code": "4.3",
      "display": "Including TBI",
      "definition": "Including TBI"
    },
    {
      "code": "5.1",
      "display": "RT >=12 Gy to a vol exposing the testicles",
      "definition": "RT >=12 Gy to a vol exposing the testicles"
    },
    {
      "code": "6.3",
      "display": "Surgery to the spinal cord, sympathetic nerves or pelvis",
      "definition": "Surgery to the spinal cord, sympathetic nerves or pelvis"
    },
    {
      "code": "6.4",
      "display": "Hypogonadal",
      "definition": "Hypogonadal"
    },
    {
      "code": "7.2",
      "display": "RT to a vol exposing the ovaries",
      "definition": "RT to a vol exposing the ovaries"
    },
    {
      "code": "8.1",
      "display": "RT >= 30 Gy to a vol exposing the head or the brain",
      "definition": "RT >= 30 Gy to a vol exposing the head or the brain"
    },
    {
      "code": "8.2",
      "display": "Cisplatin (with or without carboplatin > 1500 mg/m2)",
      "definition": "Cisplatin (with or without carboplatin > 1500 mg/m2)"
    },
    {
      "code": "9.1",
      "display": "RT to a vol exposing the pancreas",
      "definition": "RT to a vol exposing the pancreas"
    },
    {
      "code": "10.2",
      "display": "HSCT",
      "definition": "HSCT"
    },
    {
      "code": "11.1",
      "display": "RT to a volume exposing the hypothalamus or pituatary gland",
      "definition": "RT to a volume exposing the hypothalamus or pituatary gland"
    },
    {
      "code": "11.3",
      "display": "Hypothalamic or pituitary tumour",
      "definition": "Hypothalamic or pituitary tumour"
    },
    {
      "code": "11.4",
      "display": "Neurosurgery of the hypothalamus or pituitary gland",
      "definition": "Neurosurgery of the hypothalamus or pituitary gland"
    },
    {
      "code": "12.1",
      "display": "RT to a vol exposing the kidneys, heart and associated large vessels",
      "definition": "RT to a vol exposing the kidneys, heart and associated large vessels"
    },
    {
      "code": "12.3",
      "display": "Nephrectomy",
      "definition": "Nephrectomy"
    },
    {
      "code": "12.4",
      "display": "Ifosfamide",
      "definition": "Ifosfamide"
    },
    {
      "code": "12.5",
      "display": "Platinium based chemotherapy",
      "definition": "Platinium based chemotherapy"
    },
    {
      "code": "12.6",
      "display": "Nitrosureas",
      "definition": "Nitrosureas"
    },
    {
      "code": "12.7",
      "display": "Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously)",
      "definition": "Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously)"
    },
    {
      "code": "13.1",
      "display": "Cranial and/or spinal RT",
      "definition": "Cranial and/or spinal RT"
    },
    {
      "code": "13.3",
      "display": "Methotrexate",
      "definition": "Methotrexate"
    },
    {
      "code": "13.4",
      "display": "Gonadal failure",
      "definition": "Gonadal failure"
    },
    {
      "code": "13.5",
      "display": "Growth hormone deficiency",
      "definition": "Growth hormone deficiency"
    },
    {
      "code": "13.6",
      "display": "Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment",
      "definition": "Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment"
    },
    {
      "code": "13.7",
      "display": "HSCT, especially with an history of GVHD",
      "definition": "HSCT, especially with an history of GVHD"
    },
    {
      "code": "14.3",
      "display": "High dose RT",
      "definition": "High dose RT"
    },
    {
      "code": "15.1",
      "display": "Radiotherapy to a vol exposing the HP region >= 30 Gy",
      "definition": "Radiotherapy to a vol exposing the HP region >= 30 Gy"
    },
    {
      "code": "15.2",
      "display": "Surgery near or within the HP region",
      "definition": "Surgery near or within the HP region"
    },
    {
      "code": "15.3",
      "display": "CNS tumours near or within the HP region",
      "definition": "CNS tumours near or within the HP region"
    },
    {
      "code": "16.1",
      "display": "Radiotherapy to a vol exposing the HP region< 30 Gy",
      "definition": "Radiotherapy to a vol exposing the HP region< 30 Gy"
    },
    {
      "code": "16.2",
      "display": "Hydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD)",
      "definition": "Hydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD)"
    },
    {
      "code": "17.1",
      "display": "Radiotherapy to a vol exposing the HP region",
      "definition": "Radiotherapy to a vol exposing the HP region"
    },
    {
      "code": "17.5",
      "display": "hydrocephalus or cerebrospinal fluid shunt",
      "definition": "hydrocephalus or cerebrospinal fluid shunt"
    },
    {
      "code": "19.3",
      "display": "Radioiodine therapy (I-131 ablation therapy)",
      "definition": "Radioiodine therapy (I-131 ablation therapy)"
    },
    {
      "code": "19.5",
      "display": "Allogenic HSCT",
      "definition": "Allogenic HSCT"
    },
    {
      "code": "19.6",
      "display": "Total thyroidectomy",
      "definition": "Total thyroidectomy"
    },
    {
      "code": "20.1",
      "display": "RT to a vol exposing the head, brain or neck",
      "definition": "RT to a vol exposing the head, brain or neck"
    },
    {
      "code": "21.1",
      "display": "History of a central nervous system tumor",
      "definition": "History of a central nervous system tumor"
    },
    {
      "code": "21.2",
      "display": "RT to a vol exposing the brain ANY DOSE",
      "definition": "RT to a vol exposing the brain ANY DOSE"
    },
    {
      "code": "21.4",
      "display": "Brain surgery",
      "definition": "Brain surgery"
    },
    {
      "code": "21.5",
      "display": "High dose cytarabine IV (intravenous)",
      "definition": "High dose cytarabine IV (intravenous)"
    },
    {
      "code": "21.6",
      "display": "High dose MTX IV",
      "definition": "High dose MTX IV"
    },
    {
      "code": "21.7",
      "display": "Any Chemotherapy IT (intrathecal)",
      "definition": "Any Chemotherapy IT (intrathecal)"
    },
    {
      "code": "22.1",
      "display": "Vinca-Alkaloids",
      "definition": "Vinca-Alkaloids"
    },
    {
      "code": "22.2",
      "display": "Cisplatin or carboplatin",
      "definition": "Cisplatin or carboplatin"
    },
    {
      "code": "23.1",
      "display": "RT to a vol exposing the lens",
      "definition": "RT to a vol exposing the lens"
    },
    {
      "code": "24.1",
      "display": "RT to a vol exposing the eye and orbit",
      "definition": "RT to a vol exposing the eye and orbit"
    },
    {
      "code": "25.1",
      "display": "RT to a vol exposing the craniofacial area, especially after high doses and at a young age",
      "definition": "RT to a vol exposing the craniofacial area, especially after high doses and at a young age"
    },
    {
      "code": "25.3",
      "display": "Surgery to the face, especially at a young age",
      "definition": "Surgery to the face, especially at a young age"
    },
    {
      "code": "26.1",
      "display": "Surgery of the spine",
      "definition": "Surgery of the spine"
    },
    {
      "code": "26.2",
      "display": "Surgery of the chest (Does not include CVC pose)",
      "definition": "Surgery of the chest (Does not include CVC pose)"
    },
    {
      "code": "26.3",
      "display": "RT to a vol exposing the spine",
      "definition": "RT to a vol exposing the spine"
    },
    {
      "code": "26.4",
      "display": "Spinal or paraspinal malignancies",
      "definition": "Spinal or paraspinal malignancies"
    },
    {
      "code": "27.1",
      "display": "Cyclophosphamide",
      "definition": "Cyclophosphamide"
    },
    {
      "code": "27.3",
      "display": "RT to a vol exposing the bladder",
      "definition": "RT to a vol exposing the bladder"
    },
    {
      "code": "27.5",
      "display": "Cystectomy",
      "definition": "Cystectomy"
    },
    {
      "code": "27.6",
      "display": "Hysterectomy",
      "definition": "Hysterectomy"
    },
    {
      "code": "27.7",
      "display": "Pelvic surgery",
      "definition": "Pelvic surgery"
    },
    {
      "code": "27.8",
      "display": "Spinal cord surgery",
      "definition": "Spinal cord surgery"
    },
    {
      "code": "28.1",
      "display": "RT to a vol exposing the uterus only female",
      "definition": "RT to a vol exposing the uterus only female"
    },
    {
      "code": "29.1",
      "display": "RT to a vol exposing the oral cavity or salivary glands",
      "definition": "RT to a vol exposing the oral cavity or salivary glands"
    },
    {
      "code": "29.4",
      "display": "Chemotherapy",
      "definition": "Chemotherapy"
    },
    {
      "code": "30.1",
      "display": "RT to a vol exposing the gastro-intestinal tract",
      "definition": "RT to a vol exposing the gastro-intestinal tract"
    },
    {
      "code": "30.3",
      "display": "Oesophageal surgery",
      "definition": "Oesophageal surgery"
    },
    {
      "code": "30.4",
      "display": "Abdominal surgery",
      "definition": "Abdominal surgery"
    },
    {
      "code": "30.5",
      "display": "With a history of chronic GVHD",
      "definition": "With a history of chronic GVHD"
    },
    {
      "code": "31.1",
      "display": "Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2",
      "definition": "Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2"
    },
    {
      "code": "32.1",
      "display": "RT to a vol exposing the lungs",
      "definition": "RT to a vol exposing the lungs"
    },
    {
      "code": "32.3",
      "display": "Bleomycin",
      "definition": "Bleomycin"
    },
    {
      "code": "32.4",
      "display": "Busulfan",
      "definition": "Busulfan"
    },
    {
      "code": "32.5",
      "display": "BCNU Carmustine",
      "definition": "BCNU Carmustine"
    },
    {
      "code": "32.6",
      "display": "CCNU Lomustine",
      "definition": "CCNU Lomustine"
    },
    {
      "code": "32.7",
      "display": "Thoracic surgery",
      "definition": "Thoracic surgery"
    },
    {
      "code": "33.1",
      "display": "Cisplatin Any dose",
      "definition": "Cisplatin Any dose"
    },
    {
      "code": "33.2",
      "display": "Ifosfamide Any dose",
      "definition": "Ifosfamide Any dose"
    },
    {
      "code": "33.3",
      "display": "Carboplatin Any dose",
      "definition": "Carboplatin Any dose"
    },
    {
      "code": "34.1",
      "display": "RT to a volume exposing the liver",
      "definition": "RT to a volume exposing the liver"
    },
    {
      "code": "34.10",
      "display": "Chronic GVHD",
      "definition": "Chronic GVHD"
    },
    {
      "code": "34.11",
      "display": "Liver surgery",
      "definition": "Liver surgery"
    },
    {
      "code": "34.3",
      "display": "HSCT (irrespective of GVHD)",
      "definition": "HSCT (irrespective of GVHD)"
    },
    {
      "code": "34.5",
      "display": "Mercaptopurine Thioguanine",
      "definition": "Mercaptopurine Thioguanine"
    },
    {
      "code": "34.6",
      "display": "Dactinomycin",
      "definition": "Dactinomycin"
    },
    {
      "code": "34.8",
      "display": "Chronic viral hepatitis",
      "definition": "Chronic viral hepatitis"
    },
    {
      "code": "34.9",
      "display": "Sinusoidal obstruction syndrome",
      "definition": "Sinusoidal obstruction syndrome"
    },
    {
      "code": "35.1",
      "display": "HSCT (irrespective of GVHD)",
      "definition": "HSCT (irrespective of GVHD)"
    },
    {
      "code": "35.2",
      "display": "Multiple red blood cell transfusions",
      "definition": "Multiple red blood cell transfusions"
    },
    {
      "code": "36.1",
      "display": "Splenectomy",
      "definition": "Splenectomy"
    },
    {
      "code": "36.2",
      "display": "RT >= 10 Gy to a vol exposing the spleen",
      "definition": "RT >= 10 Gy to a vol exposing the spleen"
    },
    {
      "code": "36.3",
      "display": "Allogenic HSCT (with or without TBI)",
      "definition": "Allogenic HSCT (with or without TBI)"
    },
    {
      "code": "36.4",
      "display": "Autologus HSCT conditioned with TBI",
      "definition": "Autologus HSCT conditioned with TBI"
    },
    {
      "code": "37.1",
      "display": "Hereditary cancer sd",
      "definition": "Hereditary cancer sd"
    },
    {
      "code": "38.1",
      "display": "Any RT including TBI (predominantly in the RT field)",
      "definition": "Any RT including TBI (predominantly in the RT field)"
    },
    {
      "code": "38.2",
      "display": "HSCT Especially with a history of skin GvHD",
      "definition": "HSCT Especially with a history of skin GvHD"
    },
    {
      "code": "39.1",
      "display": "RT to a vol exposing the colon and rectum",
      "definition": "RT to a vol exposing the colon and rectum"
    },
    {
      "code": "40.1",
      "display": "RT to a vol exposing the oral cavity",
      "definition": "RT to a vol exposing the oral cavity"
    },
    {
      "code": "41.2",
      "display": "Anthracyclines and/or Mitoxantrone",
      "definition": "Anthracyclines and/or Mitoxantrone"
    },
    {
      "code": "41.3",
      "display": "Epipodophyllotoxins or autologous",
      "definition": "Epipodophyllotoxins or autologous"
    },
    {
      "code": "41.4",
      "display": "Autologous haematopoietic stem cell transplant",
      "definition": "Autologous haematopoietic stem cell transplant"
    },
    {
      "code": "42.1",
      "display": "Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis)",
      "definition": "Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis)"
    },
    {
      "code": "45.1",
      "display": "RT to a vol exposing the head or brain",
      "definition": "RT to a vol exposing the head or brain"
    },
    {
      "code": "46.1",
      "display": "RT between 15 and 35 Gy to a vol exposing the heart",
      "definition": "RT between 15 and 35 Gy to a vol exposing the heart"
    },
    {
      "code": "46.2",
      "display": "Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2",
      "definition": "Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2"
    },
    {
      "code": "47.1",
      "display": "RT to a vol exposing the kidney or urinary tract",
      "definition": "RT to a vol exposing the kidney or urinary tract"
    }
  ]
}